Ischemia Reperfusion Injury - Pipeline Review, H1 2017

Published: Feb, 2017 | Pages: 148 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ischemia Reperfusion Injury - Pipeline Review, H1 2017, provides an overview of the Ischemia Reperfusion Injury (Cardiovascular) pipeline landscape.

Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nutrients creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative. Symptoms include headache, bradycardia, seizures and hypertension. Risk factors include hypertension, hyperlipidemia, diabetes, insulin resistance, heart failure, altered coronary circulation, and aging.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ischemia Reperfusion Injury - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ischemia Reperfusion Injury (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 4, 26 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 22 and 4 molecules, respectively.

Ischemia Reperfusion Injury (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ischemia Reperfusion Injury (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ischemia Reperfusion Injury (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Ischemia Reperfusion Injury - Overview 7
Ischemia Reperfusion Injury - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 12
Products under Development by Companies 15
Products under Development by Universities/Institutes 17
Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development 20
Amyndas Pharmaceuticals LLC 20
Angion Biomedica Corp 20
Biomedica Management Corp (Inactive) 21
Bolder Biotechnology Inc 21
Corline Biomedical AB 22
Curatis Pharma GmbH 22
Erimos Pharmaceuticals LLC 23
Hope Pharmaceuticals Inc 23
Ischemix Inc 24
Kowa Company Ltd 24
NovelMed Therapeutics Inc 25
Omeros Corp 25
Opsona Therapeutics Ltd 26
Orexo AB 26
Pharming Group NV 27
Prolong Pharmaceuticals LLC 27
Proteo Inc 28
Prothix BV 28
Recordati SpA 29
SBI Pharmaceuticals Co Ltd 29
Ischemia Reperfusion Injury - Therapeutics Assessment 30
Assessment by Target 30
Assessment by Mechanism of Action 33
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Ischemia Reperfusion Injury - Drug Profiles 40
AM/AMBP-1 - Drug Profile 40
aminolevulinic acid hydrochloride - Drug Profile 41
ANV-6L15 - Drug Profile 42
AP-39 - Drug Profile 43
APP-103 - Drug Profile 44
BB-3 - Drug Profile 45
BBT-059 - Drug Profile 49
BMC-011 - Drug Profile 50
C1 esterase inhibitor (recombinant) - Drug Profile 51
CMX-2043 - Drug Profile 58
CRX-526 - Drug Profile 60
Curaglutide - Drug Profile 61
Des-Asp Angiotensin 1 - Drug Profile 62
EP-80317 - Drug Profile 63
FDY-5301 - Drug Profile 64
hemin (human) - Drug Profile 65
KN-93 - Drug Profile 66
MG-53 - Drug Profile 68
mirococept - Drug Profile 70
Monoclonal Antibodies to Inhibit MMP-8 for Renal Ischemia and Shock - Drug Profile 71
Monoclonal Antibody to Inhibit CD47 for Cardiovascular Disease, Kidney Transplantation and Oncology - Drug Profile 72
Monoclonal Antibody to Inhibit Complement C3 and Complement C5 for Ischemia Reperfusion Injury - Drug Profile 74
Monoclonal Antibody to Inhibit IL-16 for Renal Ischemia Reperfusion Injury - Drug Profile 75
Neutrolide - Drug Profile 76
NK-104 NP - Drug Profile 78
NP-202 - Drug Profile 79
Oligonucleotide for Oncology and Cardiovascular Diseases - Drug Profile 80
OMS-721 - Drug Profile 81
OPN-305 - Drug Profile 88
PEG-HCC - Drug Profile 91
Peptides to Modulate SRC Family Kinase for Ischemia Reperfusion Injury - Drug Profile 92
PRO-02 - Drug Profile 93
R-190 - Drug Profile 94
Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile 96
Recombinant Protein for Age Related Macular Degeneration - Drug Profile 97
Recombinant Protein to Agonize Robo1 for Ischemia Reperfusion Injury and Thrombosis - Drug Profile 98
Recombinant Protein to Antagonize EPHA4 for Amyotrophic Lateral Sclerosis, Acute Spinal Cord Injury, Sepsis and Ischemia Reperfusion Injury - Drug Profile 99
Recombinant Proteins for Ischemia Reperfusion Injury and Hypoxia - Drug Profile 100
Recombinant Proteins to Agonize PTCH1 for Ischemia Reperfusion Injury - Drug Profile 101
Recombinat Protein to Antagonize Interleukin-1 Receptor for Cardiomyopathy and Ischemia Reperfusion Injury - Drug Profile 102
Renaparin - Drug Profile 103
Sanguinate - Drug Profile 104
Small Molecule to Agonize Adenosine Receptor for Neurodegenerative Diseases and Ischemia Reperfusion Injury - Drug Profile 106
Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Drug Profile 107
Small Molecule to Inhibit HSP90 for Ischemia Reperfusion Injury - Drug Profile 108
Small Molecules for Ischemia Reperfusion Injury - Drug Profile 109
Small Molecules for Ischemia Reperfusion Injury - Drug Profile 110
Small Molecules for Ischemia Reperfusion Injury - Drug Profile 111
Small Molecules for Ischemia Reperfusion Injury and Inflammation - Drug Profile 112
Small Molecules for Myocardial Ischemia Reperfusion Injury - Drug Profile 113
Small Molecules to Activate Protein Kinase B for Ischemia Reperfusion Injury - Drug Profile 114
Small Molecules to Activate SGK-1 for Ischemic Reperfusion Injury - Drug Profile 115
Small Molecules to Inhibit PDE5 for Cardiovascular Disease - Drug Profile 116
sodium nitrite - Drug Profile 117
Synthetic Peptides for Ischemia Reperfusion Injury - Drug Profile 118
Synthetic Peptides for Oncology, Immunology and Cardiovascular Disorders - Drug Profile 119
terameprocol - Drug Profile 120
tiprelestat - Drug Profile 121
TMS-007 - Drug Profile 125
UCF-101 - Drug Profile 126
UWA-TAT - Drug Profile 127
Vanadis-03 - Drug Profile 128
VCP-746 - Drug Profile 129
YQ-23 - Drug Profile 130
Ischemia Reperfusion Injury - Dormant Projects 131
Ischemia Reperfusion Injury - Discontinued Products 134
Ischemia Reperfusion Injury - Product Development Milestones 135
Featured News & Press Releases 135
Appendix 142
Methodology 142
Coverage 142
Secondary Research 142
Primary Research 142
Expert Panel Validation 142
Contact Us 142
Disclaimer 143

List of Tables

Number of Products under Development for Ischemia Reperfusion Injury, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Ischemia Reperfusion Injury - Pipeline by Amyndas Pharmaceuticals LLC, H1 2017
Ischemia Reperfusion Injury - Pipeline by Angion Biomedica Corp, H1 2017
Ischemia Reperfusion Injury - Pipeline by Biomedica Management Corp (Inactive), H1 2017
Ischemia Reperfusion Injury - Pipeline by Bolder Biotechnology Inc, H1 2017
Ischemia Reperfusion Injury - Pipeline by Corline Biomedical AB, H1 2017
Ischemia Reperfusion Injury - Pipeline by Curatis Pharma GmbH, H1 2017
Ischemia Reperfusion Injury - Pipeline by Erimos Pharmaceuticals LLC, H1 2017
Ischemia Reperfusion Injury - Pipeline by Hope Pharmaceuticals Inc, H1 2017
Ischemia Reperfusion Injury - Pipeline by Ischemix Inc, H1 2017
Ischemia Reperfusion Injury - Pipeline by Kowa Company Ltd, H1 2017
Ischemia Reperfusion Injury - Pipeline by NovelMed Therapeutics Inc, H1 2017
Ischemia Reperfusion Injury - Pipeline by Omeros Corp, H1 2017
Ischemia Reperfusion Injury - Pipeline by Opsona Therapeutics Ltd, H1 2017
Ischemia Reperfusion Injury - Pipeline by Orexo AB, H1 2017
Ischemia Reperfusion Injury - Pipeline by Pharming Group NV, H1 2017
Ischemia Reperfusion Injury - Pipeline by Prolong Pharmaceuticals LLC, H1 2017
Ischemia Reperfusion Injury - Pipeline by Proteo Inc, H1 2017
Ischemia Reperfusion Injury - Pipeline by Prothix BV, H1 2017
Ischemia Reperfusion Injury - Pipeline by Recordati SpA, H1 2017
Ischemia Reperfusion Injury - Pipeline by SBI Pharmaceuticals Co Ltd, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Ischemia Reperfusion Injury - Dormant Projects, H1 2017
Ischemia Reperfusion Injury - Dormant Projects, H1 2017 (Contd..1), H1 2017
Ischemia Reperfusion Injury - Dormant Projects, H1 2017 (Contd..2), H1 2017
Ischemia Reperfusion Injury - Discontinued Products, H1 2017